(APTX) $0.47 --Cash $1.48 per shr --important data readout in the coming days
Aptinyx continues to believe that NYX-2925 can offer a novel therapeutic approach for fibromyalgia. To this end, the company plans to report data from ongoing fibromyalgia phase 2b study in early to mid third quarter.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.